SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MRSA - Methicillin-resistant Staphylococcus aureus -- Ignore unavailable to you. Want to Upgrade?


To: caly who wrote (96)3/9/2010 9:20:07 AM
From: Chris Forte  Respond to of 191
 
(COMTEX) Accelr8 Announces Acceptance of Scientific Presentation, and Pilot Results wi
th a New Rapid Test for a Major Emerging Resistance Threat ( BusinessWire )

DENVER, Mar 09, 2010 (BUSINESS WIRE) --
Accelr8 Technology Corporation (NYSE Amex: AXK) today announced
that it has received acceptance to present results for a study on
2-hour, culture-free, quantitative pathogen identification. The study
was co-authored with principal investigators at the Denver Health
Medical Center and the Barnes-Jewish Hospital in St. Louis. The
presentation will take place at the 110th General Meeting of the
American Society for Microbiology (ASM, www.asm.org)
to be held from May 23-27 in San Diego. Tests performed directly from
specimens accurately identified three target pathogens that are the
most
resistance--prone bacteria responsible for hospital-acquired infections
(HAI).

The company also announced the start of a study to confirm performance
of a new rapid test. It detects a threatening form of resistance that
can cause failure of the drug most commonly used to treat MRSA
"superbug" infections. There is no standard test for this important new
type of resistance, known as "hVISA." It can now be identified only
with
special equipment and procedures that are not practical for standard
hospital labs, and takes 3-5 days. Accelr8's new test only takes 3-4
hours after the initial 2-hour quantitative identification step with
the
BACcel(TM) system.

"We might think of hVISA as MRSA 2.0," said David Howson, Accelr8's
president. "Vancomycin, a drug from the 1950s, remains the drug of
choice if the physician thinks that MRSA is causing an infection.
Researchers discovered hVISA in patients who failed vancomycin therapy.
The extent of its spread is unknown because it is so difficult to
identify. With MRSA itself continuing to spread, it is essential to
have
a practical method to identify this potential next-generation MRSA."

"MRSA causes as much as 20% of HAI mortality. Bacteria that are much
more complex than MRSA cause the other 80%. Our first targets in
addition to 'Staph' include Pseudomonas and Acinetobacter,
which can cause HAI that is very difficult to manage. The study to be
presented at ASM shows that the BACcel(TM) system can accurately count
and
identify these dangerous pathogens in a single two-hour culture-free
test. This performance has never been approached by any other
technology. It demonstrates the ability to detect multiple types of
bacteria that are most likely to cause therapy to fail, and do it
quickly enough to help improve the choice of initial therapy," Howson
continued.

"Our antibiotic resistance tests follow this two-hour count and
identification to then determine whether broad resistance exists with
any of the identified pathogens. We have demonstrated the unique
ability
to test for multiple major resistance types at once, such as MRSA and
hVISA in Staphs, and ESBL and KPC now making the news about enteric
bacteria. Our resistance tests typically add two to four hours, so the
physician can receive complete results before leaving for the day. In
conjunction with test development, our study at Denver Health continues
to build its enrollment of ICU patients. We therefore expect 2010 to
show very significant advances toward making the case for rapid
diagnostics in managing critically ill patients who contract HAI,"
Howson concluded.

About Accelr8

Accelr8 Technology Corporation (www.accelr8.com)
is a developer of innovative materials and instrumentation for advanced
applications in medical instrumentation, basic research, drug
discovery,
and bio-detection. Accelr8 is developing a rapid analytical platform
for
infectious pathogens, the BACcel(TM) system, based on its innovative
surface coatings, assay processing, and detection technologies. In
addition, Accelr8 licenses certain of its proprietary technology for
use
in applications outside of Accelr8's own products.

Certain statements in this news release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Statements regarding future prospects and
developments
are based upon current expectations and involve certain risks and
uncertainties that could cause actual results and developments to
differ
materially from the forward-looking statement, including those detailed
in the company's filings with the Securities and Exchange Commission.
Accelr8 does not undertake an obligation to publicly update or revise
any forward-looking statements, whether as a result of new information
or future events.

SOURCE: Accelr8 Technology Corporation
Accelr8 Technology Corp.
Tom Geimer, 303-863-8088
tom.geimer@accelr8.com
OR
Metzger Associates
John Metzger, 303-786-7000, ext. 2202
john@metzger.com
Copyright Business Wire 2010
*** end of story ***



To: caly who wrote (96)3/9/2010 10:24:13 AM
From: Glenn Petersen2 Recommendations  Read Replies (2) | Respond to of 191
 
It's a dangerous world out there:

The Spread of Superbugs

By NICHOLAS D. KRISTOF
New York Times
March 7, 2010

Until three months ago, Thomas M. Dukes was a vigorous, healthy executive at a California plastics company. Then, over the course of a few days in December as he was planning his Christmas shopping, E. coli bacteria ravaged his body and tore his life apart.

Mr. Dukes is a reminder that as long as we’re examining our health care system, we need to scrutinize more than insurance companies. We also need to curb the way modern agribusiness madly overuses antibiotics, leaving them ineffective for sick humans.

Antibacterial drugs were revolutionary when they were introduced in the United States in 1936, virtually eliminating diseases like tuberculosis here and making surgery and childbirth far safer. But now we’re seeing increasing numbers of superbugs that survive antibiotics. One of the best-known — MRSA, a kind of staph infection — kills about 18,000 Americans annually. That’s more than die of AIDS.

Mr. Dukes, 52, picked up a kind of bacteria called ESBL-producing E. coli. While it’s conceivable that he touched a contaminated surface, a likely scenario is that he ate tainted meat, said Dr. Brad Spellberg, an infectious-diseases specialist and the author of “Rising Plague,” a book about antibiotic resistance.

Vegetarians are also vulnerable to antibiotic resistance nurtured in hog barns. Microbes swap genes, so antibiotic resistance developed in pigs can jump to microbes that infect humans in hospitals, locker rooms, schools or homes.

Routine use of antibiotics to raise livestock is widely seen as a major reason for the rise of superbugs. But Congress and the Obama administration have refused to curb agriculture’s addiction to antibiotics, apparently because of the power of the agribusiness lobby.

The ESBL E. coli initially remained in Mr. Dukes’s colon, causing no particular damage. But then he suffered an inflammation that perforated his colon — and the bacteria escaped.

Mr. Dukes began suffering stomach pains and saw his doctor, who gave him Cipro, a strong antibiotic that had previously worked against the infection. This time, the pain grew worse. The next evening, he was in surgery to remove eight inches of his colon.

A culture attributed the infection partly to ESBL E. coli. Doctors inserted a tube to administer an intravenous antibiotic in an effort to save his life.

If ESBL E. coli is frightening, there are even more potent superbugs emerging, like Acinetobacter.

“We are seeing infections caused by Acinetobacter and special bacteria called KPC Klebsiella that are literally resistant to every antibiotic that is F.D.A. approved,” Dr. Spellberg said. “These are untreatable infections. This is the first time since 1936, the year that sulfa hit the market in the U.S., that we have had this problem.”

The Infectious Diseases Society of America, an organization of doctors and scientists, has been bellowing alarms. It fears that we could slip back to a world in which we’re defenseless against bacterial diseases.

There’s broad agreement that doctors themselves overprescribe antibiotics — but also that a big part of the problem is factory farms. They feed low doses of antibiotics to hogs, cattle and poultry to make them grow faster.

A study by the Union of Concerned Scientists found that in the United States, 70 percent of antibiotics are used to feed healthy livestock, with 14 percent more used to treat sick livestock. Only about 16 percent are used to treat humans and their pets, the study found.

More antibiotics are fed to livestock in North Carolina alone than are given to humans in the entire United States
, according to the peer-reviewed Medical Clinics of North America. It concluded that antibiotics in livestock feed were “a major component” in the rise of antibiotic resistance.

Legislation introduced by Louise Slaughter, a New Yorker who is the only microbiologist in the House of Representatives, would curb the routine use of antibiotics in farming. The bill has 104 co-sponsors, but agribusiness interests have blocked it in committee — and the Obama administration and the Senate have dodged the issue.

After weeks of receiving intravenous antibiotics, Mr. Dukes is now recovering at home in Lomita, Calif. He must use a colostomy bag, but he hopes to be patched up and ready to return to work next month. Still, he knows that the ESBL E. coli remains in his gut.

“As long as it’s contained in my colon, I’m a happy camper,” he said. “But if it gets out again, I’m in trouble.”

Dr. Martin J. Blaser, chairman of the department of medicine at New York University Langone Medical Center, and a former president of the Infectious Diseases Society of America, agrees that agricultural use of antibiotics produces cheaper meat. But he says the price may be an enormous toll in human health.

“You could have very lethal pandemics,” he said. “We’re brewing some perfect storms.”

Copyright 2010 The New York Times Company

nytimes.com